<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE GlossaryTerm >
<GlossaryTerm id="CDR0000662509"><TermName>FOLFIRI-Avastin regimen</TermName><TermPronunciation>(…uh-VAS-tin REH-jih-men)</TermPronunciation><TermDefinition><DefinitionText>A chemotherapy combination used as an initial treatment of colorectal cancer that has spread. It includes the drugs leucovorin (folinic acid), fluorouracil, irinotecan hydrochloride, and bevacizumab. Also called FOLFIRI-bevacizumab and FOLFIRI-bevacizumab regimen.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000725968" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;FOLFIRI-Avastin regimen&quot;" language="en" id="_3"/><MediaLink ref="CDR0000725969" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;régimen FOLFIRI-Avastin&quot;" language="es" id="_4"/><SpanishTermName>régimen FOLFIRI-Avastin</SpanishTermName><SpanishTermDefinition><DefinitionText>Régimen de quimioterapia combinada que se usa como terapia inicial del cáncer colorrectal. Incluye los medicamentos leucovorina (ácido folínico), fluorouracilo, clorhidrato de irinotecán y bevacizumab. También se llama FOLFIRI-bevacizumab y régimen FOLFIRI-bevacizumab.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2010-04-26</DateFirstPublished><RelatedInformation><RelatedDrugSummaryRef href="CDR0000698393">FOLFIRI-BEVACIZUMAB</RelatedDrugSummaryRef></RelatedInformation></GlossaryTerm>
